Capturing and studying T cells that target cancer-specific markers
Nano and biomolecular engineered technologies for neoantigen-specific T cell capture and characterization
This study is exploring new ways to find and boost special immune cells called T cells that can target cancer-specific markers, with the goal of making cancer treatments more effective for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Institute for Systems Biology NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10901955 on NIH RePORTER |
What this research studies
This research focuses on developing advanced techniques to identify and isolate T cells that specifically recognize neoantigens associated with tumors. By utilizing engineered nanoparticles and biomolecular technologies, the project aims to enhance the capture and characterization of these T cells, which are crucial for effective cancer immunotherapy. The methodology involves analyzing T cell receptor sequences and potentially modifying patient T cells to improve their ability to fight cancer. This innovative approach seeks to overcome existing challenges in neoantigen-specific therapies and improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with tumors expressing specific neoantigens, particularly those with mutations in genes like KRAS or TP53.
Not a fit: Patients without tumors that express neoantigens or those who do not have a suitable immune response may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized cancer treatments by harnessing the body's immune response against tumors.
How similar studies have performed: Other research has shown promise in similar approaches, particularly in the clinical application of neoantigen-specific T cell therapies.
Where this research is happening
Seattle, United States
- Institute for Systems Biology — Seattle, United States (Active)
Researchers
- Principal investigator: Heath, James R. — Institute for Systems Biology
- Study coordinator: Heath, James R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.